Inhibition of Chitinase-3-like-1 by K284-6111 Reduces Atopic Skin Inflammation via Repressing Lactoferrin
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Chitinase-3-like-1 (CHI3L1) is known to induce inflammation in the progression of allergic diseases. Previous our studies revealed that 2-({3-[2-(1-cyclohexen-1-yl)ethyl]-6,7-dimethoxy-4-oxo-3,4-dihydro-2-quinazolinyl}sulfanyl)-N-(4-ethylphenyl)butanamide (K284-6111; K284), the CHI3L1 inhibiting compound, has the anti-inflammatory effect on neuroinflammation. In this study, we investigated that K284 treatment could inhibit the development of atopic dermatitis (AD). To identify the effect of K284, we used phthalic anhydride (5% PA)-induced AD animal model and in vitro reconstructed human skin model. We analyzed the expression of AD-related cytokine mediators and NF-κB signaling by Western blotting, ELISA and quantitative real-time PCR. Histological analysis showed that K284 treatment suppressed PA-induced epidermal thickening and infiltration of mast cells. K284 treatment also reduced PA-induced release of inflammatory cytokines. In addition, K284 treatment inhibited the expression of NF-κB activity in PA-treated skin tissues and TNF-α and IFN-γ-treated HaCaT cells. Protein-association network analysis indicated that CHI3L1 is associated with lactoferrin (LTF). LTF was elevated in PA-treated skin tissues and TNF-α and IFN-γ-induced HaCaT cells. However, this expression was reduced by K284 treatment. Knockdown of LTF decreased the expression of inflammatory cytokines in TNF-α and IFN-γ-induced HaCaT cells. Moreover, anti-LTF antibody treatment alleviated AD development in PA-induced AD model. Our data demonstrate that CHI3L1 targeting K284 reduces AD-like skin inflammation and K284 could be a promising therapeutic agent for AD by inhibition of LTF expression.
Abstract
Chitinase-3-like-1 (CHI3L1) is known to induce inflammation in the progression of allergic diseases. Previous our studies revealed that 2-({3-[2-(1-cyclohexen-1-yl)ethyl]-6,7-dimethoxy-4-oxo-3,4-dihydro-2-quinazolinyl}sulfanyl)-N-(4-ethylphenyl)butanamide (K284-6111; K284), the CHI3L1 inhibiting compound, has the anti-inflammatory effect on neuroinflammation. In this study, we investigated that K284 treatment could inhibit the development of atopic dermatitis (AD). To identify the effect of K284, we used phthalic anhydride (5% PA)-induced AD animal model and in vitro reconstructed human skin model. We analyzed the expression of AD-related cytokine mediators and NF-κB signaling by Western blotting, ELISA and quantitative real-time PCR. Histological analysis showed that K284 treatment suppressed PA-induced epidermal thickening and infiltration of mast cells. K284 treatment also reduced PA-induced release of inflammatory cytokines. In addition, K284 treatment inhibited the expression of NF-κB activity in PA-treated skin tissues and TNF-α and IFN-γ-treated HaCaT cells. Protein-association network analysis indicated that CHI3L1 is associated with lactoferrin (LTF). LTF was elevated in PA-treated skin tissues and TNF-α and IFN-γ-induced HaCaT cells. However, this expression was reduced by K284 treatment. Knockdown of LTF decreased the expression of inflammatory cytokines in TNF-α and IFN-γ-induced HaCaT cells. Moreover, anti-LTF antibody treatment alleviated AD development in PA-induced AD model. Our data demonstrate that CHI3L1 targeting K284 reduces AD-like skin inflammation and K284 could be a promising therapeutic agent for AD by inhibition of LTF expression.
참고문헌 (51)
- Thomsen SF, "Atopic dermatitis : natural history, diagnosis, and treatment", ISRN Allergy, 2014, pp.354250~ (2014)
- Leung DY, "New insights into atopic dermatitis", J Clin Invest, 113, pp.651~657 (2004)
- Stone SP, "Atopic dermatitis and IgE. Relationship between changes in IgE levels and severity of disease", Arch Dermatol, 112, pp.1254~1255 (1976)
- Kwak MH, "Quantitative evaluation of therapeutic effect of Liriope platyphylla on phthalic anhydride-induced atopic dermatitis in IL-4", Luc, J Ethnopharmacol, pp.2013, 148[DOI]
- 성지은, "Therapeutic effect of ethyl acetate extract from Asparagus cochinchinensis on phthalic anhydride-induced skin inflammation", Laboratory Animal Research, 32(1), pp.34~45 (2016), 한국실험동물학회
- Zhang YY, "Characteristics of peripheral blood CD4+CD25+regulatory T cells and related cytokines in severe atopic dermatitis", Eur J Dermatol, 26, pp.240~246 (2016)
- Park HJ, "Ramalin isolated from ramalina terebrata attenuates atopic dermatitis-like skin lesions in balb", c mice and cutaneous immune responses in keratinocytes and mast cells, 2016, pp.30, 1978~1987
- Brandt EB, "Th2 cytokines and atopic dermatitis", J Clin Cell Immunol, 2, pp.110~ (2011)
- Coffman FD, "Chitinase 3-Like-1(CHI3L1) : a putative disease marker at the interface of proteomics and glycomics", Crit Rev Clin Lab Sci, 45, pp.531~562 (2008)
- Blakely K, "Dupilumab, a monoclonal antibody for atopic dermatitis: A review of current literature", Skin Therapy Lett, 21, pp.1~5 (2016)
- Deleanu D, "Biological therapies for atopic dermatitis: an update", Exp Ther Med, 17, pp.1061~1067 (2019)
- Jeziorkowska R, "Topical steroid therapy in atopic dermatitis in theory and practice", Postepy Dermatol Alergol, 32, pp.162~166 (2015)
- Jarnagin K, "Crisaborole topical ointment, 2%: a nonsteroidal, topical, anti‐inflammatory phosphodiesterase 4 inhibitor in clinical development for the treatment of atopic dermatitis", J Drugs Dermatol, 15, pp.390~396 (2016)
- Kapp A, "Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug", J Allergy Clin Immunol, 110, pp.277~284 (2002)
- Meng Y, "Paeonol inhibits the development of 1-chloro-2, 4-dinitrobenzene-induced atopic dermatitis via mast and T cells in BALB", c mice, 2019, pp.19, 3217~3229
- Kzhyshkowska J, "Role of chitinase-like proteins in cancer", Biol Chem, 397, pp.231~247 (2016)
- Lee CG, "Role of chitin and chitinase", chitinase-like proteins in inflammation, tissue remodeling, and injury, 2011, pp.73, 479~501
- Yeo IJ, "Roles of chitinase 3-like 1 in the development of cancer, neurodegenerative diseases, and inflammatory diseases", Pharmacol Ther, 203, pp.107394~ (2019)
- Schimpl M, "Human YKL-39 is a pseudochitinase with retained chitooligosaccharide-binding properties", Biochem J, 446, pp.149~157 (2012)
- Sohn MH, "Genetic variation in the promoter region of chitinase 3-like 1 is associated with atopy", Am J Respir Crit Care Med, 179, pp.449~456 (2009)
- Rathcke CN, "Association of polymorphisms of the CHI3L1 gene with asthma and atopy: a populations-based study of 6514 Danish adults", PLoS One, 4, pp.e6106~ (2009)
- Kwak EJ, "Chitinase 3-like 1 drives allergic skin inflammation via Th2 immunity and M2 macrophage activation", Clin Exp Allergy, 49, pp.1464~1474 (2019)
- Salomon J, "Chitinase-3-like protein 1(ykl-40)reflects the severity of symptoms in atopic dermatitis", J Immunol Res, 2017, pp.5746031~ (2017)
- Suzuki H, "Ykl-40 promotes proliferation of cutaneous t-cell lymphoma tumor cells through extracellular signal–regulated kinase pathways", J Invest Dermatol, 140, pp.860~868 (2019)
- Semak I, "Development of dairy herd of transgenic goats as biofactory for large-scale production of biologically active recombinant human lactoferrin", Transgenic Res, 28, pp.465~478 (2019)
- Leung DY, "Cellular and immunologic mechanisms in atopic dermatitis", J Am Acad Dermatol, 44, pp.S1~S12 (2001)
- Volck B, "YKL40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils", Proc Assoc Am Physicians, 110, pp.351~360 (1998)
- Guo C, "Intranasal lactoferrin enhances α-secretase-dependent amyloid precursor protein processing via the ERK1", 2-CREB and HIF-1α pathways in an Alzheimer's disease mouse model, 2017, pp.42, 2504~2515
- Tong PL, "Oral supplementation with bovine whey-derived Ig-rich fraction and lactoferrin improves SCORAD and DLQI in atopic dermatitis", J Dermatol Sci, 85, pp.143~146 (2017)
- Choi JY, "K284-6111 prevents the amyloid betainduced neuroinflammation and impairment of recognition memory through inhibition of NF-κBmediated CHI3L1 expression", J Neuroinflammation, 15, pp.224~224 (2018)
- Lee YS, "Interleukin-32γ suppressed atopic dermatitis through inhibition of miR-205 expression via inactivation of nuclear factor-kappa B", J Allergy Clin Immunol, 146, pp.156~168 (2020)
- Szklarczyk D, "STRING v11 : protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets", Nucleic Acids Res, 47, pp.D607~D613 (2019)
- Cohen DE, "Treatment of irritant and allergic contact dermatitis", Dermatol Ther, 17, pp.334~340 (2004)
- Elias PM, "Abnormal skin barrier in the etiopathogenesis of atopic dermatitis", Curr Opin Allergy Clin Immunol, 9, pp.437~446 (2009)
- Kwak EJ, "Chitinase 3-like 1 drives allergic skin inflammation via Th2 immunity and M2 macrophage activation", Clin Exp Allergy, 49, pp.1464~1474 (2019)
- Farid AS, "Anti-inflammatory, anti-oxidant and hepatoprotective effects of lactoferrin in rats", Drug Chem Toxicol, 44, pp.286~293 (2021)
- Nordenbaek C, "YKL-40, a matrix protein of specific granules in neutrophils, is elevated in serum of patients with community-acquired pneumonia requiring hospitalization", J Infect Dis, 180, pp.1722~1726 (1999)
- Franzago M, "Collaborative model-driven software engineering : a classification framework and a research map", IEEE Trans Softw Eng, 44, pp.1146~1175 (2018)
- Antonson P, "Identification of proteins highly expressed in uterine fluid from mice with hydrometra", Biochem Biophys Res Commun, 466, pp.650~655 (2015)
- Negaoui H, "Bovine lactoferrin allergenicity as studied in murine model of allergy", Food Agric Immunol, 27, pp.711~723 (2016)
- Nagaoka K, "Human lactoferrin induces asthmatic symptoms in NC", Nga mice, 2017, pp.5, e13365~
- Fernández-Delgado L, "Allergens induce the release of lactoferrin by neutrophils from asthmatic patients", PLoS One, 10, pp.e0141278~ (2015)
- Lim JM, "Effect of peiminine on DNCB-induced atopic dermatitis by inhibiting inflammatory cytokine expression in vivo and in vitro", Int Immunopharmacol, 56, pp.135~142 (2018)
- Li L, "Cornuside inhibits mast cell-mediated allergic response by down-regulating MAPK and NF-κB signaling pathways", Biochem Biophys Res Commun, 473, pp.408~414 (2016)
- Leung DY, "Atopic dermatitis : new insights and opportunities for therapeutic intervention", J Allergy Clin Immunol, 105, pp.860~876 (2000)
- Wullaert A, "NF-κB in the regulation of epithelial homeostasis and inflammation", Cell Res, 21, pp.146~158 (2011)
- Kim MS, "Insulin-like growth factor binding protein-3 enhances etoposide-induced cell growth inhibition by suppressing the NF-κB activity in gastric cancer cells", Mol Cell Biochem, 403, pp.107~113 (2015)
- Tanaka A, "A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors", Blood, 105, pp.2324~2331 (2005)
- Park JH, "Xanthii fructus extract inhibits TNF-α", IFN-γ-induced Th2-chemokines production via blockade of NF-κB, STAT1 and p38-MAPK activation in human epidermal keratinocytes, 2015, pp.171, 85~93
- Dajee M, "Blockade of experimental atopic dermatitis via topical NF-kappaB decoy oligonucleotide", J Invest Dermatol, 126, pp.1792~1803 (2006)
- Homey B, "Cytokines and chemokines orchestrate atopic skin inflammation", J Allergy Clin Immunol, 118, pp.178~189 (2006)
